

Kaduwela, Western, SRI LANKA; Netsure Telecom Ltd. Dublin 12, Leinster, IRELAND; Northrop Grumman, Los Angeles, CA; OKB Telecom, Moscow, RUSSIA; OperTune Ltd. Oxford, Oxfordshire, UNITED KINGDOM; OSS Terrace, Cupertino, CA; OT/partners, Glen Echo, MD; Raavi Consulting Services, Hyderabad, Andhra Pradesh, INDIA; S2Net, Melbourne, Victoria, AUSTRALIA; Sigos GmbH, Nurnberg, GERMANY; Simpler Networks, Inc., Dorval, Quebec, CANADA; telconvergence GmbH, Olching, GERMANY; Telecommunications Division, Sacramento, CA; Tiscali International Network, Utrecht, NETHERLANDS; TMNG, Hilton Head Island, SC; Toyo Business Engineering Corp., Narashino, Chiba, JAPAN; Virgin Media, Hook, Hampshire, UNITED KINGDOM; Virgin Mobile, Trowbridge, Wiltshire, UNITED KINGDOM; WeDo Technologies, Lisbon, PORTUGAL; Wireless Maingate Nordic AB, Karlskrona, SWEDEN and World Wide Packets, Veradale, WA, have withdrawn as parties to this venture.

The following members have changed their names: Graftor Media Production Oy to AinaCom Oy; Amdocs to Arndocs Systems Europe Limited; Cellex to Cellex Networks System Ltd; Concept Wave Software to ConceptWave Software; Cordys Inc to Cordys Inc.; Ernst & Young (CIS) E.V. to Ernest & Young Global Telecom Center; Fastwire Pte Ltd to Fastwire; Personal to Hisashi Tada; Jacobs Rimell to JacobsRimell; Kabira Technology to Kabira Technologies; LHS to LHS Telekommunikation GmbH & Co.; Orishatech to OT/Partners; Pricewaterhouse Coopers UK to PricewaterhouseCoopers LLP; PSI AG to PSI Transcom GmbH; Ronannki Infotech Private Ltd to Ronanki Infotech Private

Ltd; <<SevenTest R&D Centre>> Co. Ltd to SevenTest R&D Centre Co. Ltd; SITRONICS Telecom Solutions to SITRONICS TS, CZ; Avici Systems Inc. to Soapstone Networks; Tele Design Servicos E Comercio De Telecomunicoes to Teleconex Comercio e Services em Tel Campinas; Telconex Comercio e Servicos em Telecommunicoes LTDA ME to Teleconex Comercio e Services em Tel Campinas; TeleManagement Forum to TM Forum; Praesidium Services Ltd to WeDo Technologies; Westwood One, Inc., to Westwood One/Metro Networks and TIM Hellas to Wind Hellas Telecommunications SA.

The following members have changed their addresses: AinaCom Oy to Hämeenlinna, FINLAND; Atos Origin to Paris La Defense Cedex, Paris, FRANCE; Digital Fairway Corporation to Toronto, Ontario, CANADA; FBBT to Belfast, County Antrim, IRELAND; LHS Telekommunikation GmbH & Co. KG to 60528 Frankfurt am Main, GERMANY; Reliance Communications Limited to Navi Mumbai, Maharashtra, INDIA; Revenue Protect Limited to Hatfield, Hertfordshire, UNITED KINGDOM; SaskTel to Regina, Saskatchewan, CANADA; Softline to Kiev, UKRAINE; Telephone and Data Systems, Inc. to Chicago, IL; Teistra Corporation to Melbourne, Victoria, AUSTRALIA and TrueBaseline Corporation to Pittsburgh, PA.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and the Forum intends to file additional written notifications disclosing all changes in membership.

On October 21, 1988, the Forum filed its original notification pursuant to Section 6(a) of the Act. The Department

of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on December 8, 1988 (53 FR 49615).

The last notification was filed with the Department on August 7, 2007. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on November 7, 2007 (72 FR 62869)

Patricia A. Brink,

Deputy Director of Operations, Antitrust Division.

[FR Doc. E8-7981 Filed 4-15-08; 8:45 am]

BILLING CODE 4410-11-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on March 14, 2008, Research Triangle Institute, Kenneth H. Davis Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
1-(1-Phenylcyclohexyl)pyrrolidine (7458)	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470)	I
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (7473)	I
1-Methyl-4-phenyl-4-propionoxypiperidine (9661)	I
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (9663)	I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)	I
2,5-Dimethoxy-4-ethylamphetamine (7399)	I
2,5-Dimethoxyamphetamine (7396)	I
3,4,5-Trimethoxyamphetamine (7390)	I
3,4-Methylenedioxyamphetamine (7400)	I
3,4-Methylenedioxyamphetamine (7405)	I
3,4-Methylenedioxy-N-ethylamphetamine (7404)	I
3-Methylfentanyl (9813)	I
3-Methylthiofentanyl (9833)	I
4-Bromo-2,5-dimethoxyamphetamine (7391)	I
4-Bromo-2,5-dimethoxyphenethylamine (7392)	I
4-Methyl-2,5-dimethoxyamphetamine (7395)	I
4-Methylaminorex (cis isomer) (1590)	I
4-Methoxyamphetamine (7411)	I
5-Methoxy-3,4-methylenedioxyamphetamine (7401)	I

Drug	Schedule
5-Methoxy-N,N-diisopropyltryptamine (7439)	
Acetorphine (9319)	
Acetyl-alpha-methylfentanyl (9815)	
Acetyldihydrocodeine (9051)	
Acetylmethadol (9601)	
Allylprodine (9602)	
Alphacetylmethadol except levo-alphacetylmethadol (9603)	
Alpha-ethyltryptamine (7249)	
Alphameprodine (9604)	
Alphamethadol (9605)	
Alpha-methylfentanyl (9814)	
Alpha-methylthiofentanyl (9832)	
Alpha-methyltryptamine (7432)	
Aminorex (1585)	
Benzethidine (9606)	
Benzylmorphine (9052)	
Betacetylmethadol (9607)	
Beta-hydroxy-3-methylfentanyl (9831)	
Beta-hydroxyfentanyl (9830)	
Betameprodine (9608)	
Betamethadol (9609)	
Betaprodine (9611)	
Bufotenine (7433)	
Cathinone (1235)	
Clonitazene (9612)	
Codeine methylbromide (9070)	
Codeine-N-Oxide (9053)	
Cyprenorphine (9054)	
Desomorphine (9055)	
Dextromoramide (9613)	
Diampromide (9615)	
Diethylthiambutene (9616)	
Diethyltryptamine (7434)	
Difenoxin (9168)	
Dihydromorphine (9145)	
Dimenoxadol (9617)	
Dimpheptanol (9618)	
Dimethylthiambutene (9619)	
Dimethyltryptamine (7435)	
Dioxaphetyl butyrate (9621)	
Dipipanone (9622)	
Drotebanol (9335)	
Ethylmethylthiambutene (9623)	
Etonitazene (9624)	
Etorphine except HCl (9056)	
Etoperidine (9625)	
Fenethylamine (1503)	
Furethidine (9626)	
Gamma Hydroxybutyric Acid (2010)	
Heroin (9200)	
Hydromorphanol (9301)	
Hydroxypethidine (9627)	
Ibogaine (7260)	
Ketobemidone (9628)	
Levomoramide (9629)	
Levophenacetylmorphan (9631)	
Lysergic acid diethylamide (7315)	
Marihuana (7360)	
Mecloqualone (2572)	
Mescaline (7381)	
Methaqualone (2565)	
Methcathinone (1237)	
Methyldesorphine (9302)	
Methyldihydromorphine (9304)	
Morpheridine (9632)	
Morphine methylbromide (9305)	
Morphine methylsulfonate (9306)	
Morphine-N-Oxide (9307)	
Myrophine (9308)	
N,N-Dimethylamphetamine (1480)	
N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (9834)	
N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (9818)	
N-Benzylpiperazine (7493)	
N-Ethyl-3-piperidyl benzilate (7482)	

Drug	Schedule
N-Ethylamphetamine (1475)	I
N-Ethyl-1-phenylcyclohexylamine (7455)	I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)	I
Nicocodeine (9309)	I
Nicomorphine (9312)	I
N-Methyl-3-piperidyl benzilate (7484)	I
Noracymethadol (9633)	I
Norlevorphanol (9634)	I
Normethadone (9635)	I
Normorphine (9313)	I
Norpipanone (9636)	I
Para-Fluorofentanyl (9812)	I
Parahehyl (7374)	I
Peyote (7415)	I
Phenadoxone (9637)	I
Phenampromide (9638)	I
Phenomorphin (9647)	I
Phenoperidine (9641)	I
Pholcodine (9314)	I
Piritramide (9642)	I
Proheptazine (9643)	I
Propiridine (9644)	I
Propiram (9649)	I
Psilocybin (7437)	I
Psilocyn (7438)	I
Racemoramide (9645)	I
Tetrahydrocannabinols (7370)	I
Thebacon (9315)	I
Thiofentanyl (9835)	I
Tilidine (9750)	I
Trimeperidine (9646)	I
1-Phenylcyclohexylamine (7460)	II
1-Piperidinocyclohexanecarbonitrile (8603)	II
Alfentanil (9737)	II
Alphaprodine (9010)	II
Amobarbital (2125)	II
Amphetamine (1100)	II
Anileridine (9020)	II
Bezitramide (9800)	II
Carfentanil (9743)	II
Codeine (9050)	II
Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Dihydrocodeine (9120)	II
Dihydroetorphine (9334)	II
Diphenoxylate (9170)	II
Ethylmorphine (9190)	II
Etorphine Hcl (9059)	II
Fentanyl (9801)	II
Glutethimide (2550)	II
Hydrocodone (9193)	II
Hydromorphone (9150)	II
Isomethadone (9226)	II
Levo-alphaacetylmethadol (9648)	II
Levomethorphan (9210)	II
Levorphanol (9220)	II
Lisdexamfetamine (1205)	II
Meperidine (9230)	II
Meperidine intermediate—A (9232)	II
Meperidine intermediate—B (9233)	II
Meperidine intermediate—C (9234)	II
Metazocine (9240)	II
Methadone (9250)	II
Methadone intermediate (9254)	II
Methamphetamine (1105)	II
Methylphenidate (1724)	II
Metopon (9260)	II
Moramide intermediate (9802)	II
Morphine (9300)	II
Nabilone (7379)	II
Opium, raw (9600)	II
Opium extracts (9610)	II
Opium fluid extract (9620)	II
Opium tincture (9630)	II
Opium, granulated (9640)	II

Drug	Schedule
Oxycodone (9143)	II
Oxymorphone (9652)	II
Pentobarbital (2270)	II
Phenazocine (9715)	II
Phencyclidine (7471)	II
Phenmetrazine (1631)	II
Phenylacetone (8501)	II
Piminodine (9730)	II
Powdered opium (9639)	II
Racemethorphan (9732)	II
Racemorphan (9733)	II
Remifentanil (9739)	II
Secobarbital (2315)	II
Sufentanil (9740)	II
Thebaine (9333)	II

The company plans to import small quantities of the listed controlled substances for the National Institute on Drug Abuse (NIDA) for research activities.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than May 16, 2008.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substances in schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: April 9, 2008.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E8-8177 Filed 4-15-08; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on March 14, 2008, Research Triangle Institute, Kenneth H. Davis Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Marihuana (7360)	I
Tetrahydrocannabinols (7370)	I
Cocaine (9041)	II

The Institute will manufacture small quantities of cocaine and marihuana derivatives for use by their customers in analytical kits, reagents, and reference standards as directed by the National Institute on Drug Abuse.

Any other such applicant, and any person who is presently registered with

DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than June 16, 2008.

Dated: April 9, 2008.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E8-8165 Filed 4-15-08; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 18, 2008, Aldrich Chemical Company Inc., DBA Isotec, 3858 Benner Road, Miamisburg, Ohio 45342-4304, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Cathinone (1235)	I
Methcathinone (1237)	I
N-Ethylamphetamine (1475)	I